IFN-γ induces PD-L1 through p38/JNK/ERK signaling pathways and counteracts the tumor promoting effect mediated by PD-L1 in Glioblastoma
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
IFN-γ induces PD-L1 through p38/JNK/ERK signaling pathways and counteracts the tumor promoting effect mediated by PD-L1 in Glioblastoma
Authors
Keywords
-
Journal
Computational Intelligence and Neuroscience
Volume 2022, Issue -, Pages 1-9
Publisher
Hindawi Limited
Online
2022-06-30
DOI
10.1155/2022/5492602
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma
- (2021) Maximilian J. Mair et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Orphan nuclear receptor TLX promotes immunosuppression via its transcriptional activation of PD-L1 in glioma
- (2021) Jiayi Zhou et al. Journal for ImmunoTherapy of Cancer
- A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials
- (2021) Elisabete Cruz Da Silva et al. Cancers
- Combination of p38 MAPK inhibitor with PD-L1 antibody effectively prolongs survivals of temozolomide-resistant glioma-bearing mice via reduction of infiltrating glioma-associated macrophages and PD-L1 expression on resident glioma-associated microglia
- (2021) Weiqi Dang et al. Brain Tumor Pathology
- The relationship between expression of PD-L1 and HIF-1α in glioma cells under hypoxia
- (2021) Xing-chen Ding et al. Journal of Hematology & Oncology
- Translating basic science discoveries into improved outcomes for glioblastoma
- (2020) Peter B Dirks et al. CLINICAL CANCER RESEARCH
- Tumor Cell Invasion in Glioblastoma
- (2020) Arabel Vollmann-Zwerenz et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Anti-PD1 up-regulates PD-L1 expression and inhibits T-cell lymphoma progression: possible involvement of an IFN-γ-associated JAK-STAT pathway
- (2019) Weili Xue et al. OncoTargets and Therapy
- Structure of the IFNγ receptor complex guides design of biased agonists
- (2019) Juan L. Mendoza et al. NATURE
- Impairing temozolomide resistance driven by glioma stem‐like cells with adjuvant immunotherapy targeting O‐acetyl GD2 ganglioside
- (2019) Julien Fleurence et al. INTERNATIONAL JOURNAL OF CANCER
- PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation
- (2018) Xin Yao Qiu et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling
- (2018) Yi Gao et al. INTERNATIONAL JOURNAL OF CANCER
- World Health Organization 2016 Classification of Central Nervous System Tumors
- (2018) Phedias Diamandis et al. NEUROLOGIC CLINICS
- Comparative effect of immunotherapy and standard therapy in patients with high grade glioma: a meta-analysis of published clinical trials
- (2018) Stefan-Alexandru Artene et al. Scientific Reports
- A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
- (2018) Miguel F. Sanmamed et al. CELL
- The Interferon-Gamma Paradox in Cancer
- (2018) M. Raza Zaidi JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
- PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer
- (2017) Xiaohui Zhang et al. International Journal of Clinical Oncology
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Genetic and immune features of resectable malignant brainstem gliomas
- (2017) Yang Zhang et al. Oncotarget
- PD-1 and PD-L1 expression in 132 recurrent nasopharyngeal carcinoma: the correlation with anemia and outcomes
- (2017) Yajuan Zhou et al. Oncotarget
- Co-expression of AFAP1-AS1 and PD-1 predicts poor prognosis in nasopharyngeal carcinoma
- (2017) Yanyan Tang et al. Oncotarget
- Treatment of Glioblastoma
- (2017) Joo Yeon Nam et al. Journal of Oncology Practice
- Dual Faces of IFN in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity
- (2016) M. Mandai et al. CLINICAL CANCER RESEARCH
- Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity
- (2016) R. D. Dorand et al. SCIENCE
- PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC
- (2016) Malaka Ameratunga et al. PLoS One
- Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
- (2015) Sonja Kleffel et al. CELL
- High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer
- (2015) Tao Qin et al. Oncotarget
- Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
- (2014) Anna Sophie Berghoff et al. NEURO-ONCOLOGY
- CTLs regulate tumor growth via cytostatic effects rather than cytotoxicity: a few T cells can influence the growth of many times more tumor cells
- (2014) Kazuhiro Kakimi et al. OncoImmunology
- Clinical impact of programmed cell death ligand 1 expression in colorectal cancer
- (2013) Raoul A. Droeser et al. EUROPEAN JOURNAL OF CANCER
- Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.
- (2013) Robert J. Wong et al. HEPATOLOGY
- Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2
- (2012) Tadashi Yokosuka et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma
- (2008) R. Yamamoto et al. BLOOD
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started